1 / 11

Prolia 60mg | Prolia 60mg Injections | denosumab | Apple pharmaceuticals

Prolia 60mg dose belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases.<br>

Emimadi
Download Presentation

Prolia 60mg | Prolia 60mg Injections | denosumab | Apple pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prolia 60mg | Prolia 60mg Injections | denosumab Apple pharmaceuticals

  2. Prolia 60mg | Prolia 60mg Injections • Prolia 60mgbelongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases. • Chemically, it exists of 2 heavy and 2 light chains. • Each light chain contains of 215 amino acids. • Each heavy chain contains of 448 amino acids with 4 intramolecular disulfides.

  3. PRESCRIBED FOR • Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture. • Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer. • Treatment for patients having to increase bone mass in women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

  4. DOSAGE Osteoporosis : • 60mg SC (subcutaneously) once every 6 months • Injection of drug should be done in upper arm, upper thigh or abdomen Giant Cell Tumor of bone : • 120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment • Injection of drug should be done in upper arm, upper thigh or abdomen OsteolyticBone Metastases of Solid Tumors : • 120mg subcutaneously every 4 weeks • Injection of drug should be done in upper arm, upper thigh or abdomen

  5. MECHANISM • Denosumablinked to RANKL, a protein which is specific for the formation, function and survival of osteoclasts, the cells necessary for bone resorption.  • Denosumabprohibits osteoclast formation, function and survival hence, reducing bone resorption and raising bone mass and strength of the bone.

  6. ADME • Peak plasma concentration: 6.75mcg/mL • Tmax: 10days • Without aggregation in Proliapharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months. Pharmacokinetics of Proliawill not affected by the binding antibodies formation. • Half-life is 25.4 days.

  7. PRECAUTION • Proliainjection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume. • Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab. • Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment • During Proliatreatment do not breastfeed your infants.

  8. DRUG INTERACTION • No formal drug-drug interaction with denosumabduring trials. • When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased CONTRAINDICATION • Proliais contraindicated in patients having Hypocalcemia, Pregnancy, Hypersensitivity

  9. LACTATION • Prolia60mg is excreted into human milk is not known. Since possible for severe side effects occurs in nursing infants from Prolia 60mg injection, a decision should be considered that to discontinue nursing or discontinue the drug by giving preference of the importance of the drug to the mother.

  10. SIDE EFFECTS • Common side effects for the patient taking Prolia 60mg as follows : Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea • Less common side effects for patients taking Prolia: • Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache

  11. Contact Us • phone No      :9987711567 • Email             :info@myapplepharma.com website • https://myapplepharma.com/prolia-60mg.php

More Related